Journal of
AIDS and HIV Research

  • Abbreviation: J. AIDS HIV Res.
  • Language: English
  • ISSN: 2141-2359
  • DOI: 10.5897/JAHR
  • Start Year: 2009
  • Published Articles: 299

Full Length Research Paper

Higher prevalence of Hepatitis B virus Infection among ARV- exposed than naive HIV-infected individuals in North Shewa Zone, Ethiopia

Yared Hailaye Bezabeh*
  • Yared Hailaye Bezabeh*
  • College of Medicine, Department of Medicine, Debre Berhan University, P.O. BOX -445, Debre Berhan, Ethiopia.
  • Search for this author on:
  • Google Scholar
Muluken Dessalegn Muluneh
  • Muluken Dessalegn Muluneh
  • Africa Medical and Research Foundation in Ethiopia, P.O.BOX -17022, Addis Ababa, Ethiopia.
  • Search for this author on:
  • Google Scholar
Solomon Gebere Sillasie
  • Solomon Gebere Sillasie
  • Department of Medical Microbiology, Medical Parasitology and Immunology, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia.
  • Search for this author on:
  • Google Scholar
Helmut Kloos
  • Helmut Kloos
  • Department of Epidemiology and Biostatistics, University of California, 2307 N. Backer Ave., Fresno, CA 93703, USA.
  • Search for this author on:
  • Google Scholar


  •  Received: 28 August 2014
  •  Accepted: 22 January 2015
  •  Published: 31 January 2015

References

Abebe A, Nokes J, Dejene A, Enquselassie F, Messele T, Cutts FT (2003). Sero epidemiology of hepatitis B virus in Addis Ababa, Ethiopia: transmission patterns and vaccine control. Epidemiol. Infect. 131: 757-770.
Crossref
 
Alter M (2006). Epidemiology of hepatitis virus and HIV co-infection. J. Hepatol. 44:56-59.
Crossref
 
Awole M, Gebre SS (2005). Seroprevalence of HBsAg and its risk factors among pregnant women in Jimma, Southwest Ethiopia. Ethiop. J. Health Dev. 19:45-50.
Crossref
 
BoFED (2009). The population report of Amhara region by zone: Reports for North ShoaZone. Amhara National Regional State Bureau of Finance and Economic Development, Bahirdar.
 
Burnett RJ, Francois G, Kew M (2005). Hepatitis B virus and human immunodeficiency virus co-infection in sub-Saharan Africa: a call for further investigation. Liver Int. 25:201-24.
Crossref
 
Chang JJ, Wightman F, Bartholomeusz A (2005). Reduced hepatitis B virus (HBV)-specific CD4-T-cell responses in Human Immunodeficiency Virus type 1-HBV- co infected individuals receiving HBV-active antiretroviral therapy. J. Virol. 79(5):3038-3051.
Crossref
 
Crane M, Sirivichayakul S, Chang JJ (2010). No increase in hepatitis B virus (HBV) specific CD8-T cells in patients with HIV-1-HBV co-infections following HBV-active HAART. J. Virol. 84(6):2657-2665.
Crossref
 
Datiko DG, Yassin MA, Chekol LT, Kabeto LE, Lindtjorn B (2008). The rate of TB-HIV co-infection depends on the prevalence of HIV infection in a community. BMC Public Health 8:266.
Crossref
 
Duncan M, Tibaus G, Pelzer A (1995). Prevalence and significance of sexually transmitted diseases among women attending clinics in Addis Ababa. Ethiop. J. Health Dev. 9:31-40.
 
Easterbrook P, Sands A, Harmanci H (2013). Challenges and priorities in the management of HIV/HBV and HIV/HCV co-infection in resource-limited areas. Semin. Liver Dis. 32:147-157.
 
Hoffmann CJ, Thio CL (2007). Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect. Dis. 7(6):402-409.
Crossref
 
Kenneth S, Marion P, Margaret K (2007). HIV and Liver Disease Forum: Conference Proceedings. Hepatology 45:1566-1577.
Crossref
 
Kim HN, Scott J, Cent A, Cook L, Morrow RA, Richardson B, Tapia K, Jerome KR, Lule G, John-Stewart G, Chung MH (2011). HBV lamivudine resistance among hepatitis B and HIV co-infected patients starting lamivudine, stavudine and nevirapine in Kenya. J. Viral Hepat. 18:e447-e452.
Crossref
 
Lacombe K, Bottero J, Lemoine M, Boyd A, Girard PM (2010). HIV/HBV co-infection: current challenges and new strategies. J. Antimicrob. Chemother. 65:10-17.
Crossref
 
Lacombe K, Rockstroh J (2012). HIV and viral hepatitis co-infections: advances and challenges. Gut:i47-i48
Crossref
 
Levy V, Robert M (2006). Antiretroviral therapy for hepatitis B virus-HIV co-infected patients: promises and pitfalls. Clin. Infect. Dis. 43:904-910.
Crossref
 
Martinez E, Blanco G, Arnaiz A (2001). Hepatotoxicity in HIV1 infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 15:1261-8.
Crossref
 
Mascolini M (2010). Older age, lower CD4 nadir, NNRTI uses predict slow CD4 recovery in Athena. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco CA.
 
Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H (2009). Hepatology: A clinical textbook. 1st ed. Flying Publisher: Dűsseldorf, Germany. p. 467.
Crossref
 
Mauss S, Thomas B, Juergen R, Christoph S, Heiner W (2013). Hepatology: A Clinical Textbook. 4th ed. Flying Publisher: Düsseldorf, Germany. p. 467.
Crossref
 
MOH (2008). Guidelines for management of opportunistic infections in adults and adolescents in Ethiopia. Federal HAPCO. Available: www.who.int/hiv/pub/guidelines/ethiopia_art.pdf
 
Nunez M, Lana R, Mendoza J (2001). Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J. AIDS 27:426-31.
Crossref
 
Peters MG (2007). Diagnosis and management of hepatitis B virus and HIV co-infection. Top. HIV Med. 15(5):163-166.
Pubmed
 
Plaza Z, Aguilera A, Mena A, Vispo E, Sierra-Enguita R, Tomé S, Pedreira J, Rodriguez C, Barreiro P, del Romero J, Soriano V, Poveda E (2013). Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B. AIDS 27(14):2219-2224.
Crossref
 
Puoti M, Airoldi M, Bruno R, Zanini B, Spinetti A, Pezzoli C, Patroni A, Castelli F, Sacchi P, Filice G, Carosi G (2002). Hepatitis B Virus co-infection in human immunodeficiency virus-infected subjects. AIDS Rev. 4:27-35.
Pubmed
 
Soriano V, Puoti M, Peters M, Benhamou Y, Sulkowski M, Zoulim F, Mauss S, Rockstroh J (2008). Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS 22(12):1399-1410.
Crossref
 
Tesga E, Mengesha B, Hanson BG (1986). Hepatitis A, B, and Delta infection in Ethiopia: a serologic survey with demographic data. Am. J. Epidemiol. 123:345-351.
 
UNAIDS (2013). Access to Antiretroviral therapy in Africa: Status Report on Progress towards the 2015 targets. UNAIDS, Geneva. Available: http://www.unaids.org/sites/default/files/media_asset/20131219_AccessARTAfricaStatusReportProgresstowards2015Targets_en_0.pdf.
 
Wilkin T (2010). What causes poor CD4-cell recovery in the setting of suppressive antiretroviral therapy? Journals Watch HIV/AIDS Clinical Care. Available from: http://www.jwatch.org/ac201004260000001/2010/04/26/what-causes-poor-cd4-cell-recovery-setting.
 
World Health Organization (WHO) (2006). Antiretroviral Therapy for HIV Infection in Adults and Adolescents Recommendations for Public Health Approach: 2006-Revision. WHO, Geneva. 26.
 
World Health Organization (WHO) (2013). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Available: http://www.who.int/hiv/pub/guidelines/arv2013/en/index.html.

 

Copyright © 2024 Author(s) retain the copyright of this article.

This article is published under the terms of the Creative Commons Attribution License 4.0

Back to Vol. 7 No. 1
Back to articles
SUBSCRIBE TO RSS
SUBMIT MANUSCRIPT
CONFERENCES